When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Status epilepticus

最后审阅: 20 Aug 2025
最后更新: 18 Feb 2025

小结

定义

病史和体格检查

关键诊断因素

  • persistent or repetitive tonic-clonic seizures with altered level of consciousness (generalized convulsive SE)
  • altered awareness/confusion (nonconvulsive SE)
完整详情

其他诊断因素

  • focal SE without impaired consciousness
  • low oxygen saturation
完整详情

危险因素

  • nonadherence to anticonvulsant drugs
  • alcohol-use disorder
  • stroke
  • refractory epilepsy
  • toxic or metabolic causes
  • processes leading to direct cortical structural damage
  • drug use
完整详情

诊断性检查

首要检查

  • anticonvulsant drug blood level
  • toxicology screen
  • comprehensive metabolic panel
  • CBC
  • ECG
  • electroencephalography (EEG)
完整详情

需考虑的检查

  • ABG
  • CT head
  • lumbar puncture
  • MRI head
  • continuous EEG (cEEG)
完整详情

治疗流程

急症处理

generalized convulsive status epilepticus

nonconvulsive status epilepticus

focal without impaired consciousness

撰稿人

作者

Emily L. Johnson, MD

Associate Professor of Neurology

Johns Hopkins Medical Institutions

Baltimore

MD

利益声明

ELJ declares that she has no competing interests.

鸣谢

Dr Emily L. Johnson would like to gratefully acknowledge Dr Ronald P. Lesser, Dr Mohammad Koubeissi, and Dr Nabil Azar, previous contributors to this topic.

利益声明

RPL or his wife have stock in the following companies, which sell health care products: Abbott Labs, Apple, Avanos, Celgene, Express Scripts, Johnson and Johnson, and Pfizer. NA declares that he has no competing interests. MK declares that he has no competing interests.

同行评议者

Maria Jose Bruzzone Giraldez, MD

Assistant Professor Epilepsy Division

University of Florida

Gainesville

FL

利益声明

None

Yvonne Hart, MBBS

Consultant Neurologist

John Radcliffe Hospital

Oxford

UK

利益声明

YH has been reimbursed by UCB Pharma Ltd, Janssen-Cilag Ltd, Pfizer Ltd, and Eisai Ltd for attending conferences; has taught at meetings sponsored by the above companies and by GlaxoSmithKline Services Unlimited; and has received payment for advisory board work from UCB Pharma Ltd, Janssen-Cilag Ltd, Eisai Ltd, and GlaxoSmithKline Services Unlimited.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

参考文献

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

关键文献

Brophy GM, Bell R, Claassen J, et al; Neurocritical Care Society Status Epilepticus Guideline Writing Committee. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012 Aug;17(1):3-23. 摘要

Glauser T, Shinnar S, Gloss D. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr. 2016 Jan-Feb;16(1):48-61.全文  摘要

National Institute for Health and Care Excellence (UK). Epilepsies in children, young people and adults. Apr 2022 [internet publication].全文

参考文献

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
  • Differentials

    • Nonepileptic SE
    • Delirium
    • Coma
    更多 鉴别诊断
  • Guidelines

    • Emergency management of the pediatric patient with convulsive status epilepticus
    • Evidence-based guideline: treatment of convulsive status epilepticus in children and adults
    更多 Guidelines
  • Patient information

    Epilepsy: what is it?

    Epilepsy: what are the treatment options?

    More Patient information
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer